微创医疗(00853.HK)：微创(上海)医疗机器人增资引入珠海高瓴等多家投资者
格隆汇9月1日丨微创医疗(00853.HK)发布公告，2020年8月31日，该附属公司(公司全资附属上海默化人工智能科技有限公司)及目标公司与该等投资者及上海常隆订立协议，据此，该附属公司同意向该等投资者转让目标公司7.1429%注册资本以获取人民币15亿元；目标公司的现有股东上海常隆同意向该等投资者转让目标公司2.3809%的注册资本，以获取人民币5亿元；及该等投资者同意向目标公司注入额外资本合共人民币15亿元。
目标公司微创(上海)医疗机器人有限公司为一间于中国成立的有限责任公司，专注于手术机器人研发与产业化。目标公司于2014年开始手术机器人研发与产业化突破，致力于面向微创伤手术最前沿发展需求，创新性提供能够挽救病人生命或改善其生活质量的一体化智能手术解决方案。经过多年研发创新与产业积累，目标公司已发展成为掌握手术机器人全链条底层技术的科创公司。目标公司三大细分领域的3款旗舰产品图迈™ Toumai™腔镜手术机器人、鸿鹄™Skywalker™关节置换手术机器人、蜻蜓眼™DFVision™ 三维电子腹腔镜均已进入国家药品监督管理局创新医疗器械“绿色通道”特别审批程序，成为中国目前唯一拥有3项“绿色通道”的手术机器人公司。
该等投资者包括珠海高瓴崇恒股权投资合伙企业(有限合伙)、天津熔浩企业管理合伙企业(有限合伙)、嘉兴贝霖泓润创业投资合伙企业(有限合伙)、天津远翼元福企业管理中心(有限合伙)、易方慧达创业投资(广东)合伙企业(有限合伙)及易方易达(广东)投资合伙企业(有限合伙)。
该等交易完成后，目标公司投资后估值约为人民币225亿元，而该附属公司于目标公司的股权将由64.7560%减少至53.7722%。目标公司将仍为公司的附属公司。根据协议的条款，该等投资者有权要求目标公司按相等于以下总额的赎回价赎回该等投资者所持有目标公司的股权：有关投资者所持有目标公司股权的原始认购或购买价的100%；及10%的年利率。
公告表示，集团处于快速成长及发展阶段。由于集团很多产品涉及尖端技术，研发、临床试验、监管注册及商业化涉及巨大成本。因此，集团对其所有集团公司实施其发展计划有大量的资金需求。向目标公司引入该等投资者旨在为目标公司发展提供额外资金及把握目标公司的增长机会。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
